News | August 02, 2024
Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Subscribe To Our Newsletter & Stay Updated
